Surgical management of colorectal cancer metastases to the liver: multimodality approach and a single institutional experience

Papers of special note have been highlighted as: ▪ of interest ▪▪ of considerable interest

References

• 1  Siegel R, Naishadham D, Jemal A. Cancer statistics, 2012. CA Cancer J. Clin.62(1),10–29 (2012).
  MedlineGoogle Scholar
• 2  Eisenberg B, Decosse JJ, Harford F et al. Carcinoma of the colon and rectum – the natural history reviewed in 1704 patients. Cancer.49,1131–1134 (1982).
  Medline CASGoogle Scholar
• 3  Steele G, Ravikumar TS. Resection of hepatic metastases from colorectal cancer – biologic perspectives. Ann. Surg.210,127–138 (1989).
  MedlineGoogle Scholar
• 4  Bengtsson G, Carlsson G, Hafstrom L et al. Natural history of patients with untreated liver metastases from colorectal cancer. Am. J. Surg.141,586–589 (1981).
  Medline CASGoogle Scholar
• 5  Bozzetti F, Bignami P, Morabito A et al. Patterns of failure following surgical resection of colorectal cancer liver metastases – rationale for a multimodal approach. Ann. Surg.205,264–270 (1987).
  Medline CASGoogle Scholar
• 6  de Jong MC, Pulitano C, Ribero D et al. Rates and patterns of recurrence following curative intent surgery for colorectal liver metastasis – an international multiinstitutional analysis of 1669 patients. Ann. Surg.250,440–448 (2009).
  MedlineGoogle Scholar
• 7  Scheele J, Stang R, Altendorf-Hofmann A et al. Resection of colorectal liver metastases. World J. Surg.19,59–71(1995).
  Medline CASGoogle Scholar
• 8  Gertsch P. A historical perspective on colorectal liver metastases and peritoneal carcinomatosis: similar results, different treatments. Surg. Oncol. Clin. N. Am.12,531–541 (2003).
  MedlineGoogle Scholar
• 9  Scheele J, Stangl R, Altendorfhofmann A. Hepatic metastases from colorectalcarcinoma – impact of surgical resection on the natural history. Br. J. Surg.77,1241–1246 (1990).
  Medline CASGoogle Scholar
• 10  Assumpcao L, Choti MA, Gleisner AL et al. Patterns of recurrence following liver resection for colorectal metastases – effect of primary rectal tumor site. Arch. Surg.143,743–749 (2008).
  MedlineGoogle Scholar
• 11  Wei AC, Greig PD, Grant D et al. Survival after hepatic resection for colorectal metastases: a 10-year experience. Ann. Surg. Oncol.13,668–676 (2006).
  MedlineGoogle Scholar
• 12  Rees M, Tekkis PP, Welsh FKS et al. Evaluation of long-term survival after hepatic resection for metastatic colorectal cancer – a multifactorial model of 929 patients. Ann. Surg.247,125–135 (2008).
  MedlineGoogle Scholar
• 13  Stangl R, Altendorfhofmann A, Charnley RM et al. Factors influencing the natural history of colorectal liver metastases. Lancet343,1405–1410 (1994).
  Medline CASGoogle Scholar
• 14  Wagner JS, Adson MA, Vanheerden JA et al. The natural history of hepatic metastases from colorectal cancer – a comparison with resective treatment. Ann. Surg.199,502–508 (1984).
  Medline CASGoogle Scholar
• 15  Miller G, Biernacki P, Kemeny NE et al. Outcomes after resection of synchronous or metachronous hepatic and pulmonary colorectal metastases. J. Am. Coll. Surg.205,231–236 (2007).
  MedlineGoogle Scholar
• 16  Charnsangavej C, Clary B, Fong YM et al. Selection of patients for resection of hepatic colorectal metastases: expert consensus statement. Ann. Surg. Oncol.13,1261–1268 (2006).▪▪ Excellent summary of the diagnostic workup, patient selection, timing of surgical intervention and resectability criteria in patients with colorectal liver metastases, including recommendations based on the available evidence.
  MedlineGoogle Scholar
• 17  Abdalla EK, Adam R, Bilchik AJ et al. Improving resectability of hepatic colorectal metastases: expert consensus statement. Ann. Surg. Oncol.13,1271–1280 (2006).▪▪ Consensus statement summarizing treatment options available to patients who present with unresectable colorectal hepatic metastases with the goal of downstaging their disease and improving their eligiblity for hepatic resection; including, chemotherapy, portal vein embolization and radiofrequency ablation.
  MedlineGoogle Scholar
• 18  Krieger PM, Tamandl D, Herberger B et al. Evaluation of chemotherapy-associated liver injury in patients with colorectal cancer liver metastases using indocyanine green clearance testing. Ann. Surg. Oncol.18,1644–1650 (2011).
  MedlineGoogle Scholar
• 19  Jaeck D, Nakano H, Bachellier P et al. Significance of hepatic pedicle lymph node involvement in patients with colorectal liver metastases: a prospective study. Ann. Surg. Oncol.9,430–438 (2002).
  MedlineGoogle Scholar
• 20  Adam R, de Haas RJ, Wicherts DA et al. Is hepatic resection justified after chemotherapy in patients with colorectal liver metastases and lymph node involvement? J. Clin. Oncol.26,3672–3680 (2008).
  MedlineGoogle Scholar
• 21  Fakih MG, Padmanabhan A. CEA monitoring in colorectal cancer – what you should know. Oncology (Williston Park)20,579–587 (2006).
  MedlineGoogle Scholar
• 22  Filella X, Molina R, Pique JM et al. Use of Ca-19–19 in the early detection of recurrences in colorectal cancer – comparison with CEA. Tumor Biol.15,1–6 (1994).
  Medline CASGoogle Scholar
• 23  Kneuertz PJ, Maithel SK, Staley CA et al. Chemotherapy-associated liver injury: impact on surgical management of colorectal cancer liver metastases. Ann. Surg. Oncol.18,181–190 (2011).
  MedlineGoogle Scholar
• 24  Niekel MC, Bipat S, Stoker J. Diagnostic imaging of colorectal liver metastases with CT, MR imaging, FDG PET, and/or FDG PET/CT: a meta-analysis of prospective studies including patients who have not previously undergone treatment. Radiology257,674–684 (2010).
  MedlineGoogle Scholar
• 25  Bipat S, van Leeuwen MS, Comans EFI et al. Colorectal liver metastases: CT, MR imaging, and PET for diagnosis – meta-analysis. Radiology237,123–131 (2005).
  MedlineGoogle Scholar
• 26  Selzner MK, Hany TF, Wildbrett P et al. Does the novel PET/CT imaging modality impact on the treatment of patients with metastatic colorectal cancer of the liver? Ann. Surg.240,1027–1036 (2004).
  MedlineGoogle Scholar
• 27  Wiering B, Ruers TJM, Krabbe PFM et al. Comparison of multiphase CT, FDG-PET and intra-operative ultrasound in patients with colorectal liver metastases selected for surgery. Ann. Surg. Oncol.14,818–826 (2007).
  Medline CASGoogle Scholar
• 28  Goshen E, Davidson T, Zwas ST et al. PET/CT in the evaluation of response to treatment of liver metastases from colorectal cancer with bevacizumab and irinotecan. Technol. Cancer Res. Treat.5,37–43 (2006).
  Medline CASGoogle Scholar
• 29  Sietses C, Meijerink MR, Meijer S et al. The impact of intraoperative ultrasonography on the surgical treatment of patients with colorectal liver metastases. Surg. Endosc.24,1917–1922 (2010).
  Medline CASGoogle Scholar
• 30  Mazzoni G, Napoli A, Mandetta S et al. Intra-operative ultrasound for detection of liver metastases from colorectal cancer. Liver Int.28,88–94 (2008).
  MedlineGoogle Scholar
• 31  Rahusen FD, Cuesta MA, Borgstein PJ et al. Selection of patients for resection of colorectal metastases to the liver using diagnostic laparoscopy and laparoscopic ultrasonography. Ann. Surg.230,31–37 (1999).
  Medline CASGoogle Scholar
• 32  Erlichman C, Fine S, Wong A et al. A randomized trial of Fluorouracil and Folinic acid in patients with metastatic colorectal carcinoma. J. Clin. Oncol.6,469–475 (1988).
  Medline CASGoogle Scholar
• 33  de Gramont A, Figer A, Seymour M et al. Leucovorin and fluorouracil with or without oxaliplatin as first-line treatment in advanced colorectal cancer. J. Clin. Oncol.18,2938–2947 (2000).
  Medline CASGoogle Scholar
• 34  Saltz LB, Cox JV, Blanke C et al. Irinotecan plus fluorouracil and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.343,905–914 (2000).
  Medline CASGoogle Scholar
• 35  Goldberg RM, Sargent DJ, Morton RF et al. A randomized controlled trial of fluorouracil plus leucovorin, irinotecan and oxaliplatin combinations in patients with previously untreated metastatic colorectal cancer. J. Clin. Oncol.22,23–30 (2004).
  Medline CASGoogle Scholar
• 36  Hurwitz H, Fehrenbacher L, Novotny W et al. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer. N. Engl. J. Med.350,2335–2342 (2004).▪ A randomized clinical trial that establishes the benefit of bevacizumab in combination with multidrug chemotherapy in the setting of metastatic colorectal cancer.
  Medline CASGoogle Scholar
• 37  Saltz LB, Clarke S, az-Rubio E et al. Bevacizumab in combination with oxaliplatin-based chemotherapy as first-line therapy in metastatic colorectal cancer: a randomized Phase III study. J. Clin. Oncol.26,2013–2019 (2008).
  Medline CASGoogle Scholar
• 38  Cunningham D, Humblet Y, Siena S et al. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer. N. Engl. J. Med.351,337–345 (2004).
  Medline CASGoogle Scholar
• 39  Dy GK, Hobday TJ, Nelson G et al. Long-term survivors of metastatic colorectal cancer treated with systemic chemotherapy alone: a North Central Cancer Treatment Group review of 3811 patients, N0144. Clin. Colorectal Cancer8,88–93 (2009).
  Google Scholar
• 40  Tournigand C, Andre T, Achille E et al. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study. J. Clin. Oncol.22,229–237 (2004).▪ Randomized trial comparing the sequence of modern chemotherapy regimens for the treatment of colorectal metastases and providing further evidence for the use of oxaliplatin and irinotecan in combination with fluorouracil/leucovorin.
  Medline CASGoogle Scholar
• 41  Masi G, Loupakis F, Pollina L et al. Long-term outcome of initially unresectable metastatic colorectal cancer patients treated with 5-fluorouracil/leucovorin, oxaliplatin, and irinotecan (FOLFOXIRI) followed by radical surgery of metastases. Ann. Surg.249,420–425 (2009).
  MedlineGoogle Scholar
• 42  Chua TC, Saxena A, Liauw W et al. Systematic review of randomized and nonrandomized trials of the clinical response and outcomes of neoadjuvant systemic chemotherapy for resectable colorectal liver metastases. Ann. Surg. Oncol.17,492–501 (2010).
  MedlineGoogle Scholar
• 43  Blazer DG, Kishi Y, Maru DM et al. Pathologic response to preoperative chemotherapy: a new outcome end point after resection of hepatic colorectal metastases. J. Clin. Oncol.26,5344–5351 (2008).
  MedlineGoogle Scholar
• 44  Adam R, Delvart V, Pascal G et al. Rescue surgery for unresectable colorectal liver metastases downstaged by chemotherapy – a model to predict long-term survival. Ann. Surg.240,644–657 (2004).
  MedlineGoogle Scholar
• 45  Bismuth H, Adam R, Levi F et al. Resection of nonresectable liver metastases from colorectal cancer after neoadjuvant chemotherapy. Ann. Surg.224,509–520 (1996).
  Medline CASGoogle Scholar
• 46  Abdalla EK, Hicks ME, Vauthey JN. Portal vein embolization: rationale, technique and future prospects. Br. J. Surg.88,165–175 (2001).
  Medline CASGoogle Scholar
• 47  Abulkhir A, Limongelli P, Healey AJ et al. Preoperative portal vein embolization for major liver resection – a meta-analysis. Ann. Surg.247,49–57 (2008).
  MedlineGoogle Scholar
• 48  Ribero D, Abdalla EK, Madoff DC et al. Portal vein embolization before major hepatectomy and its effects on regeneration, resectability and outcome. Br. J. Surg.94,1386–1394 (2007).
  Medline CASGoogle Scholar
• 49  Farges O, Belghiti J, Kianmanesh R et al. Portal vein embolization before right hepatectomy – prospective clinical trial. Ann. Surg.237,208–217 (2003).
  MedlineGoogle Scholar
• 50  Vauthey JN, Chaoui A, Do KA et al. Standardized measurement of the future liver remnant prior to extended liver resection: methodology and clinical associations. Surgery127,512–519 (2000).
  Medline CASGoogle Scholar
• 51  Azoulay D, Castaing D, Smail A et al. Resection of nonresectable liver metastases from colorectal cancer after percutaneous portal vein embolization. Ann. Surg.231,480–486 (2000).
  Medline CASGoogle Scholar
• 52  Narita M, Oussoultzoglou E, Jaeck D et al. Two-stage hepatectomy for multiple bilobar colorectal liver metastases. Br. J. Surg.98,1463–1475 (2011).
  Medline CASGoogle Scholar
• 53  Wicherts DA, Miller R, de Haas RJ et al. Long-term results of two-stage hepatectomy for irresectable colorectal cancer liver metastases. Ann. Surg.248,994–1005 (2008).
  MedlineGoogle Scholar
• 54  Chun YS, Vauthey JN, Ribero D et al. Systemic chemotherapy and two-stage hepatectomy for extensive bilateral colorectal liver metastases: perioperative safety and survival. J. Gastrointest. Surg.11,1498–1504 (2007).
  MedlineGoogle Scholar
• 55  Siperstein AE, Berber E, Ballem N et al. Survival after radiofrequency ablation of colorectal liver metastases – 10-year experience. Ann. Surg.246,559–567 (2007).
  MedlineGoogle Scholar
• 56  Veltri A, Sacchetto P, Tosetti I et al. Radiofrequency ablation of colorectal liver metastases: small size favorably predicts technique effectiveness and survival. Cardiovasc. Intervent. Radiol.31,948–956 (2008).
  MedlineGoogle Scholar
• 57  Abdalla EK, Vauthey JN, Ellis LM et al. Recurrence and outcomes following hepatic resection, radiofrequency ablation, and combined resection/ablation for colorectal liver metastases. Ann. Surg.239,818–824 (2004).▪ Retrospective review comparing patients with colorectal liver metastases who were treated with hepatic resection, resection plus radiofrequency ablation, radiofrequency ablation alone or chemotherapy alone. Although subject to selection bias, these results suggest the superiority of resection over radiofrequency ablation and the superiority of radiofrequency ablation over chemotherapy.
  MedlineGoogle Scholar
• 58  Gray B, Van Hazel G, Hope M et al. Randomized trial of SIR-Spheres plus chemotherapy vs chemotherapy alone for treating patients with liver metastases from primary large bowel cancer. Ann. Oncol.12,1711–1720 (2001).
  Medline CASGoogle Scholar
• 59  Hendlisz A, Van den Eynde M, Peeters M et al. Phase III trial comparing protracted intravenous fluorouracil infusion alone or with Yttrium-90 resin microspheres radioembolization for liver limited metastatic colorectal cancer refractory to standard chemotherapy. J. Clin. Oncol.28,3687–3694 (2010).
  Medline CASGoogle Scholar
• 60  Martin RCG, Robbins K, Tomalty D et al. Transarterial chemoembolization (TACE) using irinotecan-loaded beads for the treatment of unresectable metastases to the liver in patients with colorectal cancer: an interim report. World J. Surg. Oncol.7,80 (2009).
  MedlineGoogle Scholar
• 61  Fiorentini G, Aliberti C, Turrisi G et al. Intraarterial hepatic chemoembolization of liver metastases from colorectal cancer adopting irinotecan-eluting beads: results of a Phase II clinical study. In Vivo.21,1085–1091 (2007).
  Medline CASGoogle Scholar
• 62  SanzAltamira PM, Spence LD, Huberman MS et al. Selective chemoembolization in the management of hepatic metastases in refractory colorectal carcinoma – a Phase II trial. Dis. Colon Rectum40,770–775 (1997).
  Medline CASGoogle Scholar
• 63  Aliberti C, Fiorentini G, Muzzio PC, et al. Trans-arterial chemoembolization of metastatic colorectal carcinoma to the liver adopting DC bead, drug-eluting bead loaded with irinotecan: results of a Phase II clinical study. Anticancer Res.31,4581–4587 (2011).
  Medline CASGoogle Scholar
• 64  Goodman KA, Wiegner EA, Maturen KE et al. Dose-escalation study of single-fraction stereotactic body radiotherapy for liver malignancies. Int. J. Radiat. Oncol. Biol. Phys.78,486–493, (2010).
  MedlineGoogle Scholar
• 65  Katz AW, Carey-Sampson M, Muhs AG et al. Hypofractionated stereotactic body radiation therapy (SBRT) for limited hepatic metastases. Int. J. Radiat. Oncol. Biol. Phys.67,793–798 (2007).
  MedlineGoogle Scholar
• 66  Wulf J, Guckenberger M, Haedinger U et al. Stereotactic radiotherapy of primary liver cancer and hepatic metastases. Acta Oncol.45,838–847 (2006).
  MedlineGoogle Scholar
• 67  Nordlinger B, Sorbye H, Glimelius B et al. Perioperative chemotherapy with FOLFOX4 and surgery versus surgery alone for resectable liver metastases from colorectal cancer (EORTC Intergroup trial 40983): a randomized controlled trial. Lancet371,1007–1016 (2008).▪▪ Large randomized trial showing improved progression-free survival in patients with colorectal liver metastases treated with perioperative chemotherapy plus hepatic resection versus hepatic resection alone.
  Medline CASGoogle Scholar
• 68  Ihemelandu C, Levine EA, Aklilu M et al. Optimal timing of systemic therapy in resectable colorectal liver metastases. Am. Surg. (In Press).
  Google Scholar
• 69  Gruenberger B, Tamandl D, Schueller J et al. Bevacizumab, capecitabine, and oxaliplatin as neoadjuvant therapy for patients with potentially curable metastatic colorectal cancer. J. Clin. Oncol.26,1830–1835 (2008).
  Medline CASGoogle Scholar
• 70  Gruenberger B, Scheithauer W, Punzengruber R et al. Importance of response to neoadjuvant chemotherapy in potentially curable colorectal cancer liver metastases. BMC Cancer8,120 (2008).
  MedlineGoogle Scholar
• 71  Nakano H, Oussoultzoglou E, Rosso E et al. Sinusoidal injury increases morbidity after major hepatectomy in patients with colorectal liver metastases receiving preoperative chemotherapy. Ann. Surg.247,118–124 (2008).
  MedlineGoogle Scholar
• 72  Vauthey JN, Pawlik TM, Ribero D et al. Chemotherapy regimen predicts steatohepatitis and an increase in 90 day mortality after surgery for hepatic colorectal metastases. J. Clin. Oncol.24,2065–2072 (2006).
  Medline CASGoogle Scholar
• 73  Rubbia-Brandt L, Audard V, Sartoretti P et al. Severe hepatic sinusoidal obstruction associated with oxaliplatin-based chemotherapy in patients with metastatic colorectal cancer. Ann. Oncol.15,460–466 (2004).
  Medline CASGoogle Scholar
• 74  Fernandez FG, Ritter J, Goodwin JW et al. Effect of steatohepatitis associated with irinotecan or oxaliplatin pretreatment on resectability of hepatic colorectal metastases. J. Am. Coll. Surg.200,845–853 (2005).
  MedlineGoogle Scholar
• 75  Langer B, Bleiberg H, Labianca R et al. Fluorouracil (FU) plus l-leucovorin (l-LV) versus observation after potentially curative resection of liver or lung metastases from colorectal cancer (CRC): results of the ENG (EORTC/NCIC CTG/GIVIO) randomized trial. Proc. Am. Soc. Clin. Oncol.21(Suppl.),149a (2002).
  Google Scholar
• 76  Portier G, Elias D, Bouche O et al. Multicenter randomized trial of adjuvant fluorouracil and folinic acid compared with surgery alone after resection of colorectal liver metastases: FFCD ACHBTH AURC 9002 trial. J. Clin. Oncol.24,4976–4982 (2006).
  Medline CASGoogle Scholar
• 77  Mitry E, Fields ALA, Bleiberg H et al. Adjuvant chemotherapy after potentially curative resection of metastases from colorectal cancer: a pooled analysis of two randomized trials. J. Clin. Oncol.26,4906–4911 (2008).▪ This study pools data from two randomized controlled trials evaluating the efficacy of adjuvant chemotherapy following hepatic resection for colorectal liver metastases. The results suggest improved progression-free and overall survival in patients who receive adjuvant chemotherapy.
  Medline CASGoogle Scholar
• 78  Parks R, Gonen M, Kemeny N et al. Adjuvant chemotherapy improves survival after resection of hepatic colorectal metastases: Analysis of data from two continents. J. Am. Coll. Surg.204,753–761 (2007).
  MedlineGoogle Scholar
• 79  Ychou M, Hohenberger W, Thezenas S et al. A randomized Phase III study comparing adjuvant 5-fluorouracil/folinic acid with FOLFIRI in patients following complete resection of liver metastases from colorectal cancer. Ann. Oncol.20,1964–1970 (2009).
  Medline CASGoogle Scholar
• 80  Kemeny MM, Adak S, Gray B et al. Combined-modality treatment for resectable metastatic colorectal carcinoma to the liver: Surgical resection of hepatic metastases in combination with continuous infusion of chemotherapy – an intergroup study. J. Clin. Oncol.20,1499–1505 (2002).
  MedlineGoogle Scholar
• 81  Kemeny N, Huang Y, Cohen AM et al. Hepatic arterial infusion of chemotherapy after resection of hepatic metastases from colorectal cancer. N. Engl. J. Med.341,2039–2048 (1999).
  Medline CASGoogle Scholar
• 82  Lorenz M, Muller HH, Schramm H et al. Randomized trial of surgery versus surgery followed by adjuvant hepatic arterial infusion with 5-fluorouracil and folinic acid for liver metastases of colorectal cancer. Ann. Surg.228,756–762 (1998).
  Medline CASGoogle Scholar
• 83  Mocellin S, Pilati P, Lise M et al. Meta-analysis of hepatic arterial infusion for unresectable liver metastases from colorectal cancer: the end of an era? J. Clin. Oncol.25,5649–5654 (2007).
  MedlineGoogle Scholar
• 84  de Jong MC, Mayo SC, Pulitano C et al. Repeat curative intent liver surgery is safe and effective for recurrent colorectal liver metastasis: results from an international multi-institutional analysis. J. Gastrointest. Surg.13,2141–2150 (2009).
  MedlineGoogle Scholar
• 85  Lopez P, Marzano E, Piardi T et al. Repeat hepatectomy for liver metastases from colorectal primary cancer: a review of the literature. J. Visc. Surg.149,e97–e103 (2012).
  Medline CASGoogle Scholar
• 86  Vetto JT, Hughes KS, Rosenstein R et al. Morbidity and mortality of hepatic resection for metastatic colorectal-carcinoma. Dis. Colon Rectum33,408–413 (1990).
  Medline CASGoogle Scholar
• 87  Nordlinger B, Parc R, Delva E et al. Hepatic resection for colorectal liver metastases – influence on survival of preoperative factors and surgery for recurrences in 80 patients. Ann. Surg.205,256–263 (1987).
  Medline CASGoogle Scholar
• 88  Holm A, Bradley E, Aldrete JS. Hepatic resection of metastasis from colorectal-carcinoma – morbidity, mortality, and pattern of recurrence. Ann. Surg.209,428–434 (1989).
  Medline CASGoogle Scholar
• 89  Kortz WJ, Meyers WC, Hanks JB et al. Hepatic resection for metastatic cancer. Ann. Surg.199,182–186 (1984).
  Medline CASGoogle Scholar
• 90  House MG, Ito H, Gonen M et al. Survival after hepatic resection for metastatic colorectal cancer: trends in outcomes for 1600 patients during two decades at a single institution. J. Am. Coll. Surg.210,744–752 (2010).▪ Large retrospective study showing improved trends in operative mortality and disease-specific survival from hepatic resections performed for colorectal liver metastases from 1999 to 2004 compared with those performed from 1985 to 1988.
  MedlineGoogle Scholar
• 91  Choti MA, Sitzmann JV, Tiburi MF et al. Trends in long-term survival following liver resection for hepatic colorectal metastases. Ann. Surg.235,759–765 (2002).
  MedlineGoogle Scholar
• 92  Nathan H, de Jong MC, Pulitano C et al. Conditional survival after surgical resection of colorectal liver metastasis: an international multi-institutional analysis of 949 patients. J. Am. Coll. Surg.210,755–764 (2010).▪▪ One of the largest available series reporting long-term outcomes following hepatic resection for colorectal liver metastases. It includes an in-depth analysis of patient characteristic and survival trends over time and evaluates the efficacy of several prognostic scoring systems, as well as reporting conditional survival statistics.
  MedlineGoogle Scholar
• 93  Cescon M, Vetrone G, Grazi GL et al. Trends in perioperative outcome after hepatic resection analysis of 1500 consecutive unselected cases over 20 years. Ann. Surg.249,995–1002 (2009).
  MedlineGoogle Scholar
• 94  Jamagin WR, Gonen M, Fong YM et al. Improvement in Perioperative outcome after hepatic resection – analysis of 1803 consecutive cases over the past decade. Ann. Surg.236,397–407 (2002).
  MedlineGoogle Scholar
• 95  Figueras J, Torras J, Valls C et al. Surgical resection of colorectal liver metastases in patients with expanded indications: a single-center experience with 501 patients. Dis. Colon Rectum50,478–488 (2007).
  MedlineGoogle Scholar
• 96  Tomlinson JS, Jarnagin WR, DeMatteo RP et al. Actual 10-year survival after resection of colorectal liver metastases defines cure. J. Clin. Oncol.25,4575–4580 (2007).▪ Analysis of patients with at least 10 years of follow-up after hepatic resection for colorectal liver metastases. The survival curve from these patients plateaus by 10 years with 99 of 102 10-year survivors remaining disease-free suggesting that cure is possible in a subset of patients.
  MedlineGoogle Scholar
• 97  Wang X, Hershman DL, Abrams JA et al. Predictors of survival after hepatic resection among patients with colorectal liver metastasis. Br. J. Cancer97,1606–1612 (2007).
  Medline CASGoogle Scholar
• 98  Nordlinger B, Guiguet M, Vaillant JC et al. Surgical resection of colorectal carcinoma metastases to the liver – a prognostic scoring system to improve case selection based on 1568 patients. Cancer77,1254–1262 (1996).
  Medline CASGoogle Scholar
• 99  Fong Y, Fortner J, Sun RL et al. Clinical score for predicting recurrence after hepatic resection for metastatic colorectal cancer – analysis of 1001 consecutive cases. Ann. Surg.230,309–318 (1999).
  Medline CASGoogle Scholar
• 100  Minagawa M, Yamamoto J, Kosuge T et al. Simplified staging system for predicting the prognosis of patients with resectable liver metastasis – development and validation. Arch. Surg.142,269–276 (2007).
  MedlineGoogle Scholar
• 101  Adam R, Pascal G, Castaing D et al. Tumor progression while on chemotherapy – a contraindication to liver resection for multiple colorectal metastases? Ann. Surg.240,1052–1064 (2004).
  MedlineGoogle Scholar
• 102  Kattan MW, Gonen M, Jarnagin WR et al. A nomogram for predicting disease-specific survival after hepatic resection for metastatic colorectal cancer. Ann. Surg.247,282–287 (2008).
  MedlineGoogle Scholar
• 103  Dindo D, Demartines N, Clavien PA. Classification of surgical complications – a new proposal with evaluation in a cohort of 6336 patients and results of a survey. Ann. Surg.240,205–213 (2004).
  MedlineGoogle Scholar